Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)
Introduction: Evaluation of health-related quality-of-life (HRQoL) and symptom improvement were preplanned secondary objectives for the overall population and posthoc analyses for epidermal growth factor receptor (EGFR) mutation-positive/negative subgroups in IPASS. Methods: HRQoL was assessed using...
Saved in:
Main Authors: | Thongprasert S., Duffield E., Saijo N., Wu Y.-L., Yang J.C.-H., Chu D.-T., Liao M., Chen Y.-M., Kuo H.-P., Negoro S., Lam K.C., Armour A., Magill P., Fukuoka M. |
---|---|
Format: | Article |
Language: | English |
Published: |
2014
|
Online Access: | http://www.scopus.com/inward/record.url?eid=2-s2.0-80054882063&partnerID=40&md5=a3b134d1b53530e6aaf637e86637e5cf http://www.ncbi.nlm.nih.gov/pubmed/22011650 http://cmuir.cmu.ac.th/handle/6653943832/2978 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Language: | English |
Similar Items
-
Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)
by: Sumitra Thongprasert, et al.
Published: (2018) -
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
by: Tony S. Mok, et al.
Published: (2018) -
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
by: Tony S. Mok, et al.
Published: (2018) -
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
by: Wu Y., et al.
Published: (2017) -
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
by: Yi Long Wu, et al.
Published: (2018)